Journal of Clinical Endocrinology & Metabolism, Vol 75, 1470-1473, Copyright © 1992 by Endocrine Society

ARTICLES

The role of body mass in the response to growth hormone therapy

PM Martha Jr, EO Reiter, N Davila, MA Shaw, JH Holcombe and G Baumann
Department of Pediatrics, Baystate Medical Center, Springfield, Massachusetts 01199.

Obesity is associated with normal or increased growth despite diminished GH secretion compared to lean children. The mechanism by which adequate growth is maintained in the presence of low GH levels is unknown, but is possibly mediated at the GH receptor level. To probe this hypothesis, we examined the relationship between GH responsivity, body mass index (BMI) and plasma GH-binding protein (GH-BP)/receptor level in 43 GH-deficient children during treatment with a fixed dose of GH (0.18 mg/kg.week). Before treatment, BMI [expressed as standard deviation score (SDS) for age (BMI-SDS)] did not correlate with either growth velocity or serum insulin-like growth factor-I (IGF-I). In contrast, after 12 months of GH therapy BMI-SDS correlated directly with plasma IGF-I (P < 10(-5)) and growth velocity (P < 10(-3)). These findings parallel those obtained for GH-BP vs. the response to GH, suggesting that BMI and GH-BP are covariants. The interrelationships among BMI, GH-BP, and response to GH were further probed by multiple regression analysis. Partial correlation coefficients vs. response to GH were consistently stronger for GH-BP than for BMI-SDS, indicating that GH-BP is the dominant factor between these two covariants in determining responsiveness to GH. The data suggest a primary role for GH-BP/receptor levels in determining GH action, with secondary but significant effects of nutrition and degree of adiposity. The latter may be mediated through the impact of nutrition and body mass on GH- BP/receptor levels.

This article has been cited by other articles:

				N. Bouhours-Nouet, F. Gatelais, F. Boux de Casson, S. Rouleau, and R. Coutant The Insulin-Like Growth Factor-I Response to Growth Hormone Is Increased in Prepubertal Children with Obesity and Tall Stature J. Clin. Endocrinol. Metab., February 1, 2007; 92(2): 629 - 635. [Abstract] [Full Text] [PDF]

				R. Coutant, F. B. de Casson, S. Rouleau, O. Douay, E. Mathieu, F. Gatelais, N. Bouhours-Nouet, C. Voinot, M. Audran, and J. M. Limal Divergent Effect of Endogenous and Exogenous Sex Steroids on the Insulin-Like Growth Factor I Response to Growth Hormone in Short Normal Adolescents J. Clin. Endocrinol. Metab., December 1, 2004; 89(12): 6185 - 6192. [Abstract] [Full Text] [PDF]

				R. Coutant, F. Boux de Casson, S. Rouleau, O. Douay, E. Mathieu, M. Audran, and J. M. Limal Body Composition, Fasting Leptin, and Sex Steroid Administration Determine GH Sensitivity in Peripubertal Short Children J. Clin. Endocrinol. Metab., December 1, 2001; 86(12): 5805 - 5812. [Abstract] [Full Text] [PDF]

				T. Amit, M. B. H. Youdim, and Z.'e. Hochberg Does Serum Growth Hormone (GH) Binding Protein Reflect Human GH Receptor Function? J. Clin. Endocrinol. Metab., March 1, 2000; 85(3): 927 - 932. [Abstract] [Full Text]

				P. Saenger, K. M. Attie, J. DiMartino-Nardi, R. Hintz, L. Frahm, and J. W. Frane Metabolic Consequences of 5-Year Growth Hormone (GH) Therapy in Children Treated with GH for Idiopathic Short Stature J. Clin. Endocrinol. Metab., September 1, 1998; 83(9): 3115 - 3120. [Abstract] [Full Text]

				B. Kriström, B. Carlsson, S. Rosberg, L. M. S. Carlsson, and K. Albertsson-Wikland Short-Term Changes in Serum Leptin Levels Provide a Strong Metabolic Marker for the Growth Response to Growth Hormone Treatment in Children J. Clin. Endocrinol. Metab., August 1, 1998; 83(8): 2735 - 2741. [Abstract] [Full Text]

				S. Fisker, N. Vahl, J. O. L. Jorgensen, J. S. Christiansen, and H. Orskov Abdominal Fat Determines Growth Hormone-Binding Protein Levels in Healthy Nonobese Adults J. Clin. Endocrinol. Metab., January 1, 1997; 82(1): 123 - 128. [Abstract] [Full Text] [PDF]